Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026)

Lexeo Therapeutics has disclosed Research & Development across 5 years of filings, most recently posting $15.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $15.7 million, down 8.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.1 million (down 38.93% YoY), and the FY2025 annual result was $63.8 million, down 13.89% from the prior year.
• Research & Development came in at $15.7 million for Q1 2026 at Lexeo Therapeutics, roughly flat from $15.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $23.4 million in Q3 2024 to a low of -$44.9 million in Q4 2023.
• The 5-year median for Research & Development is $15.7 million (2024), against an average of $11.7 million.
• Across the five-year window, Research & Development sank 494.48% in 2023 and surged 140.89% in 2024, its largest moves.
• Lexeo Therapeutics' Research & Development stood at $11.4 million in 2022, then tumbled by 494.48% to -$44.9 million in 2023, then soared by 140.89% to $18.4 million in 2024, then retreated by 14.54% to $15.7 million in 2025, then increased by 0.05% to $15.7 million in 2026.
• The last three Research & Development figures came in at $15.7 million (Q1 2026), $15.7 million (Q3 2025), and $14.7 million (Q2 2025), per Business Quant data.